No evidence for persistence of BCR-ABL–positive cells in patients in molecular remission after conventional allogeneic transplantation for chronic myeloid leukemia

Appropriate monitoring of patients after allogeneic stem cell transplantation (SCT) for chronic myeloid leukemia (CML) is crucial, because the response to donor lymphocyte infusions is superior in the case of cytogenetic or molecular relapse compared with hematological relapse.[1][1] Chomel et al

[1]  A. Kitzis,et al.  Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. , 2000, Blood.

[2]  J. Goldman,et al.  Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. , 1999, Experimental hematology.

[3]  A. Zinsmeister,et al.  A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. , 1998, Blood.

[4]  J. Goldman,et al.  Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. , 1996, Blood.

[5]  R. Krahl,et al.  Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells. , 1995, Experimental hematology.

[6]  J. Radich,et al.  Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. , 1995, Blood.

[7]  D. Ginsburg,et al.  Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. , 1992, Blood.